title: MOLECULAR EFFECTS OF AMINE DERIVATIVES OF PHENOTHIAZINE ON CANCER CELLS C-32 AND SNB-19 IN VITRO.
abstract: Cancer therapy is challenging for scientists because of low effectiveness of so far existing therapies (especially in case of great invasiveness and advanced tumor stage). Such need for new drug development and search for more efficient new findings in therapeutical applications is therefore still valid. There are also conducted studies on modifying so far existing drugs and their new methods of usage in oncology practice. One of them is phenothiazine and its derivatives which are used in psychiatric treatment for years. They also exhibit antiprion, antiviral, antibacterial and antiprotozoal properties. Cytotoxic activity, influence on proliferation, ability to induce apoptosis suggest also a possibility of phenothiazine derivatives usage in cancer cells termination. The aim of our the study was to evaluate the influence of two amine derivatives of phenothiazine on cancer cells in vitro. Amelanotic melanoma C-32 cell line (ATCC) and glioma SNB-19 cells (DSMZ) were used in this study and two derivatives were analyzed. In view of examined substances tumor potential toxicity cells proliferation and viability exposed to phenothiazine derivatives were established. Cell cycle regulatory genes expression (TP53 and CDKN1A), S-phase marker--H3 gene and intracellular apoptosis pathway genes (BAX, BCL-2) were analyzed using RT-QPCR method. The influence of examined derivatives on total cell oxidative status (TOS), total antioxidative status (TAS), malondialdehyde concentration (MDA) and superoxide dismutase activity (SOD) were analyzed. As a result, examined phenothiazine derivatives cytotoxic action on C-32 and SNB-19 and also cells proliferation inhibition were determined. Cell cycle regulatory genes (TP53, CDKN1A) expression and protein products of genes involved in mitochondial apoptosis pathway (BAX, BCL-2) expression are changed by the presence of phenothiazine derivatives during culturing. There were also noted small changes in redox potential in cells exposed to two mentioned phenothiazine derivatives.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Latocha
authors.forename: Andrzej
authors.initials: A
authors.lastname: Zięba
authors.forename: Renata
authors.initials: R
authors.lastname: Polaniak
authors.forename: Dariusz
authors.initials: D
authors.lastname: Kuśmierz
authors.forename: Ada
authors.initials: A
authors.lastname: Nowosad
authors.forename: Magdalena
authors.initials: M
authors.lastname: Jurzak
authors.forename: Ewa
authors.initials: E
authors.lastname: Romuk
authors.forename: Mirosława
authors.initials: M
authors.lastname: Kokocińska
authors.forename: Elektra
authors.initials: E
authors.lastname: Sliupkas-Dyrda
mesh_terms: D000588:Amines / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics; D016158:Genes, p53; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D018328:Melanoma, Amelanotic / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010640:Phenothiazines / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology
chemical_list: D000588:Amines; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D010640:Phenothiazines; D019253:Proto-Oncogene Proteins c-bcl-2